---
title: "Readiness for long-acting injectable HIV treatment and PrEP among Ugandan clinic clients"
id: "medrxiv-7-readiness-to-start-long-acting-injectable-hiv-treatment-and-prevention-and"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-7-readiness-to-start-long-acting-injectable-hiv-treatment-and-prevention-and"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.10.14.26365499v1?rss=1"
published_at: "2026-10-15T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Readiness for long-acting injectable HIV treatment and PrEP among Ugandan clinic clients
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-7-readiness-to-start-long-acting-injectable-hiv-treatment-and-prevention-and
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.10.14.26365499v1?rss=1)
- **Published At:** 2026-10-15T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Cross-sectional survey of 225 clinic clients at Mildmay Hospital and Kajjansi Health Centre IV in central Uganda assessed readiness to start **long-acting injectable** HIV treatment or prevention. - Readiness was defined as preferring initiation immediately or within three months; 108 participants (48.0%) met this definition, while 111 (49.3%) sought more information. - Only six participants (2.7%) preferred initiation in six to twelve months; investigators therefore categorized most into immediate/soon or information-seeking groups. - Age modified readiness among people living with HIV: 15–24-year-olds showed 80.8% readiness versus 34.4% among those ≥25 years (aPR 2.35, 95% CI 1.63–3.38). - Among **PrEP**-service clients, readiness was 39.2% for 15–24-year-olds and 41.4% for ≥25-year-olds (aPR 0.95, 95% CI 0.60–1.50); the age-by-service interaction had p=0.002. - Adjusted models linked clinic staff information (aPR 1.94, 95% CI 1.42–2.66), belief in greater effectiveness (aPR 2.00, 95% CI 1.43–2.80), and higher benefit scores (one-point increase aPR 3.27, 95% CI 2.36–4.55) with higher readiness. - Higher concern scores (one-point increase aPR 0.70, 95% CI 0.60–0.80) and more frequent financial difficulty (aPR 0.68, 95% CI 0.48–0.96) were associated with lower readiness. - Across service and readiness groups, the leading condition for accepting injectable options was experiencing fewer side effects. - Investigators recommend that programs assess intended initiation timing alongside willingness and address safety, appointment flexibility, privacy and affordability through counselling and service planning. - Study ethics approval and data-access procedures are documented; participant-level data are not publicly available due to ethical restrictions and require institutional approval for access.
## Clinical Analysis & Structured Key Points
Readiness to start long acting injectable HIV treatment and prevention and conditions for acceptance among clinic clients in Uganda | medRxiv Skip to main content Readiness to start long acting injectable HIV treatment and prevention and conditions for acceptance among clinic clients in Uganda View ORCID Profile Stephen Charles Olet , View ORCID Profile Wandera Uthmaan Muluga , View ORCID Profile Drake Musoki , Bernard Raymond Kihumuro , Farid Muluga , View ORCID Profile Ivan Ssebandeke , Fiona Among , View ORCID Profile Chad D. Stecher , View ORCID Profile David Musoke doi: https://doi.org/10.64898/2026.10.14.26365499 Stephen Charles Olet 1 Makerere University School of Public Health; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Stephen Charles Olet For correspondence: solet{at}musph.ac.ug Wandera Uthmaan Muluga 2 Makerere University School of Public Health, Kampala, Uganda; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Wandera Uthmaan Muluga Drake Musoki 3 Mildmay Research Centre Uganda, Wakiso, Uganda; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Drake Musoki Bernard Raymond Kihumuro 4 Joint Clinical Research Centre, Kampala, Uganda; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Farid Muluga 2 Makerere University School of Public Health, Kampala, Uganda; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Ivan Ssebandeke 2 Makerere University School of Public Health, Kampala, Uganda; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Ivan Ssebandeke Fiona Among 5 St Francis Hospital Nsambya, Kampala, Uganda; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Chad D. Stecher 6 College of Health Solutions, Arizona State University, Phoenix, Arizona, USA Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Chad D. Stecher David Musoke 2 Makerere University School of Public Health, Kampala, Uganda; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for David Musoke Abstract Info/History Metrics Data/Code Preview PDF Abstract Long-acting injectable human immunodeficiency virus (HIV) medicines expand treatment and prevention choices, but willingness to use them does not establish readiness to begin. We examined readiness to start these options, associated factors and conditions for acceptance among people living with HIV and pre-exposure prophylaxis (PrEP)-service clients in Uganda. This cross-sectional study analysed 225 participants at Mildmay Hospital and Kajjansi Health Centre IV in central Uganda. Readiness meant preferring initiation immediately or within three months. Modified Poisson regression estimated adjusted prevalence ratios (aPRs) and 95% confidence intervals (CIs), including age-by-service-group interaction. Separate models examined informational, perceptual and financial factors, adjusting for service group, age and sex. Logistic marginal standardisation checked demographic and expanded age comparisons. Overall, 108 participants (48.0%) were ready to start injectable HIV treatment or prevention, 111 (49.3%) wanted more information about these options, and six (2.7%) preferred initiation in six to twelve months. Readiness was 80.8% among people living with HIV aged 15–24 years and 34.4% among those aged 25 years or older (aPR 2.35, 95% CI 1.63–3.38). Corresponding proportions among PrEP-service clients were 39.2% and 41.4% (aPR 0.95, 95% CI 0.60–1.50; interaction p=0.002). In separate adjusted models, clinic-staff information (aPR 1.94, 95% CI 1.42–2.66), belief in greater effectiveness (2.00, 1.43–2.80) and a one-point increase in benefit score (3.27, 2.36–4.55) were associated with higher readiness. A one-point increase in concern score (0.70, 0.60–0.80) and financial difficulty sometimes or more often (0.68, 0.48–0.96) were associated with lower readiness. Fewer side effects was the leading condition for accepting injectable HIV treatment or prevention across service and readiness groups. Nearly half of participants were ready to start, while a similar proportion wanted further information about injectable options. Programmes should assess intended initiation timing alongside willingness and address safety, appointment flexibility, privacy and affordability through counselling and service planning. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Mildmay Uganda Research Ethics Committee approved the study (MUREC-2026-1828) I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability Participant-level data are not publicly available because [confirmed ethical or legal restriction]. Researchers should direct data-access requests to Mildmay Research Centre Uganda at info{at}mildmayuganda.or.ug. Access requires approval from Mildmay Research Centre Uganda and a signed data-use agreement to protect participant confidentiality. Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Back to top Previous Posted October 15, 2026. Download PDF Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Readiness to start long acting injectable HIV treatment and prevention and conditions for acceptance among clinic clients in Uganda Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Readiness to start long acting injectable HIV treatment and prevention and conditions for acceptance among clinic clients in Uganda Stephen Charles Olet , Wandera Uthmaan Muluga , Drake Musoki , Bernard Raymond Kihumuro , Farid Muluga , Ivan Ssebandeke , Fiona Among , Chad D. Stecher , David Musoke medRxiv 2026.10.14.26365499; doi: https://doi.org/10.64898/2026.10.14.26365499 Share This Article: Copy Citation Tools Readiness to start long acting injectable HIV treatment and prevention and conditions for acceptance among clinic clients in Uganda Stephen Charles Olet , Wandera Uthmaan Muluga , Drake Musoki , Bernard Raymond Kihumuro , Farid Muluga , Ivan Ssebandeke , Fiona Among , Chad D. Stecher , David Musoke medRxiv 2026.10.14.26365499; doi: https://doi.org/10.64898/2026.10.14.26365499 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (629) Allergy and Immunology (914) Anesthesia (343) Cardiovascular Medicine (4924) Dentistry and Oral Medicine (488) Dermatology (422) Emergency Medicine (667) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1657) Epidemiology (16123) Forensic Medicine (35) Gastroenterology (1228) Genetic and Genomic Medicine (7174) Geriatric Medicine (740) Health Economics (1081) Health Informatics (5184) Health Policy (1452) Health Systems and Quality Improvement (1809) Hematology (596) HIV/AIDS (1363) Infectious Diseases (except HIV/AIDS) (16401) Intensive Care and Critical Care Medicine (1187) Medical Education (687) Medical Ethics (156) Nephrology (733) Neurology (7443) Nursing (373) Nutrition (1111) Obstetrics and Gynecology (1274) Occupational and Environmental Health (1022) Oncology (3692) Ophthalmology (1077) Orthopedics (400) Otolaryngology (461) Pain Medicine (488) Palliative Medicine (142) Pathology (715) Pediatrics (1837) Pharmacology and Therapeutics (745) Primary Care Research (780) Psychiatry and Clinical Psychology (6040) Public and Global Health (9887) Radiology and Imaging (2480) Rehabilitation Medicine and Physical Therapy (1495) Respiratory Medicine (1258) Rheumatology (655) Sexual and Reproductive Health (792) Sports Medicine (591) Surgery (794) Toxicology (109) Transplantation (314) Urology (299)
## Related Clinical Research

- [Monocyte phenotypes associated with peri‑coronary inflammation in people with and without HIV](https://medichelpline.com/clinical-feed/frontiers-in-immunology-15-distinct-monocyte-phenotypes-are-associated-with-peri-coronary-inflammation-in.md)
- [Self-reported tuberculosis prevalence and vulnerability factors in six rural Indian districts](https://medichelpline.com/clinical-feed/plos-one-16-self-reported-prevalence-of-tuberculosis-and-selected-associated-vulnerability.md)
- [Augmented Trials Mixing Randomized and Observational Data for Postnatal HIV Prophylaxis](https://medichelpline.com/clinical-feed/medrxiv-1-combining-randomized-and-observational-data-the-case-of-postnatal-prophylaxis.md)
- [PanChol phase 1 booster study: durability after one dose and safety/immunogenicity of a second ora](https://medichelpline.com/clinical-feed/medrxiv-11-phase-1-durability-study-of-a-single-dose-of-the-live-attenuated-cholera.md)
- [Reflecting on 50 Years of Interleukin-2: Advancements in Immunotherapy and Retrovirology](https://medichelpline.com/clinical-feed/stat-news-2-opinion-50-years-ago-my-colleagues-and-i-pursued-basic-research-science-that.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.